Cargando…
Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample
Biological bases of autism spectrum disorder (ASD) include both genetic and epigenetic causes. Patients with ASD show anomalies in the profile of certain plasma amino acids, including neuroactive amino acids. Monitoring plasma amino acids may be relevant for patient care and interventions. We evalua...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955282/ https://www.ncbi.nlm.nih.gov/pubmed/36832540 http://dx.doi.org/10.3390/children10020412 |
_version_ | 1784894312456126464 |
---|---|
author | Randazzo, Martina Prato, Adriana Messina, MariaAnna Meli, Concetta Casabona, Antonino Rizzo, Renata Barone, Rita |
author_facet | Randazzo, Martina Prato, Adriana Messina, MariaAnna Meli, Concetta Casabona, Antonino Rizzo, Renata Barone, Rita |
author_sort | Randazzo, Martina |
collection | PubMed |
description | Biological bases of autism spectrum disorder (ASD) include both genetic and epigenetic causes. Patients with ASD show anomalies in the profile of certain plasma amino acids, including neuroactive amino acids. Monitoring plasma amino acids may be relevant for patient care and interventions. We evaluated the plasma amino acid profile in samples extracted from dry blood spots by electrospray ionization-tandem mass spectrometry. Fourteen amino acids and eleven amino acid ratios were examined in patients with ASD and intellectual disability (ID), and neurotypical control subjects (TD). The amino acid profile in the ASD group showed reduced levels of ornithine (p = 0.008), phenylalanine (p = 0.042) and tyrosine (p = 0.013). The statistically significant amino acid ratios were Leu+Val/Phe+Tyr (p = 0.002), Tyr/Leu (p = 0.007) and Val/Phe (p = 0.028), such differences remaining significant only in the comparison between ASD and TD. Finally, a positive correlation emerged between the score of the restricted and repetitive behavior on ADOS-2 and the citrulline levels in the ASD group (p = 0.0047). To conclude, patients with ASD may show a distinguishable metabolic profile useful for studying their metabolic pathways in order to develop screening tests and targeted therapies. |
format | Online Article Text |
id | pubmed-9955282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99552822023-02-25 Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample Randazzo, Martina Prato, Adriana Messina, MariaAnna Meli, Concetta Casabona, Antonino Rizzo, Renata Barone, Rita Children (Basel) Article Biological bases of autism spectrum disorder (ASD) include both genetic and epigenetic causes. Patients with ASD show anomalies in the profile of certain plasma amino acids, including neuroactive amino acids. Monitoring plasma amino acids may be relevant for patient care and interventions. We evaluated the plasma amino acid profile in samples extracted from dry blood spots by electrospray ionization-tandem mass spectrometry. Fourteen amino acids and eleven amino acid ratios were examined in patients with ASD and intellectual disability (ID), and neurotypical control subjects (TD). The amino acid profile in the ASD group showed reduced levels of ornithine (p = 0.008), phenylalanine (p = 0.042) and tyrosine (p = 0.013). The statistically significant amino acid ratios were Leu+Val/Phe+Tyr (p = 0.002), Tyr/Leu (p = 0.007) and Val/Phe (p = 0.028), such differences remaining significant only in the comparison between ASD and TD. Finally, a positive correlation emerged between the score of the restricted and repetitive behavior on ADOS-2 and the citrulline levels in the ASD group (p = 0.0047). To conclude, patients with ASD may show a distinguishable metabolic profile useful for studying their metabolic pathways in order to develop screening tests and targeted therapies. MDPI 2023-02-20 /pmc/articles/PMC9955282/ /pubmed/36832540 http://dx.doi.org/10.3390/children10020412 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Randazzo, Martina Prato, Adriana Messina, MariaAnna Meli, Concetta Casabona, Antonino Rizzo, Renata Barone, Rita Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample |
title | Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample |
title_full | Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample |
title_fullStr | Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample |
title_full_unstemmed | Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample |
title_short | Neuroactive Amino Acid Profile in Autism Spectrum Disorder: Results from a Clinical Sample |
title_sort | neuroactive amino acid profile in autism spectrum disorder: results from a clinical sample |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955282/ https://www.ncbi.nlm.nih.gov/pubmed/36832540 http://dx.doi.org/10.3390/children10020412 |
work_keys_str_mv | AT randazzomartina neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample AT pratoadriana neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample AT messinamariaanna neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample AT meliconcetta neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample AT casabonaantonino neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample AT rizzorenata neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample AT baronerita neuroactiveaminoacidprofileinautismspectrumdisorderresultsfromaclinicalsample |